Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

Eline Boon, Winette T.A. van der Graaf, Hans Gelderblom, Margot E.T. Tesselaar, Robert J.J. van Es, Sjoukje F. Oosting, Remco de Bree, Esther van Meerten, Ann Hoeben, Ludi E. Smeele, Stefan M. Willems, Max J.H. Witjes, Jan Buter, Robert J. Baatenburg de Jong, Uta E. Flucke, Petronella G.M. Peer, Judith V.M.G. Bovée, Carla M.L. Van Herpen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. Results: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively). Conclusion: In patients younger than 75 years of age with surgically resected high- and intermediate-grade osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo-)adjuvant chemotherapy in patients amenable to chemotherapy.

Original languageEnglish
Pages (from-to)140-146
Number of pages7
JournalHead and Neck
Volume39
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Cite this

Boon, E., van der Graaf, W. T. A., Gelderblom, H., Tesselaar, M. E. T., van Es, R. J. J., Oosting, S. F., ... Van Herpen, C. M. L. (2017). Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head and Neck, 39(1), 140-146. https://doi.org/10.1002/hed.24556
Boon, Eline ; van der Graaf, Winette T.A. ; Gelderblom, Hans ; Tesselaar, Margot E.T. ; van Es, Robert J.J. ; Oosting, Sjoukje F. ; de Bree, Remco ; van Meerten, Esther ; Hoeben, Ann ; Smeele, Ludi E. ; Willems, Stefan M. ; Witjes, Max J.H. ; Buter, Jan ; Baatenburg de Jong, Robert J. ; Flucke, Uta E. ; Peer, Petronella G.M. ; Bovée, Judith V.M.G. ; Van Herpen, Carla M.L. / Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. In: Head and Neck. 2017 ; Vol. 39, No. 1. pp. 140-146.
@article{64cc2d9816a54d14b4c378bbb413f255,
title = "Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults",
abstract = "Background: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. Results: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55{\%}. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively). Conclusion: In patients younger than 75 years of age with surgically resected high- and intermediate-grade osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo-)adjuvant chemotherapy in patients amenable to chemotherapy.",
keywords = "(neo-)adjuvant, chemotherapy, head and neck neoplasms, mandible, maxilla, osteosarcoma",
author = "Eline Boon and {van der Graaf}, {Winette T.A.} and Hans Gelderblom and Tesselaar, {Margot E.T.} and {van Es}, {Robert J.J.} and Oosting, {Sjoukje F.} and {de Bree}, Remco and {van Meerten}, Esther and Ann Hoeben and Smeele, {Ludi E.} and Willems, {Stefan M.} and Witjes, {Max J.H.} and Jan Buter and {Baatenburg de Jong}, {Robert J.} and Flucke, {Uta E.} and Peer, {Petronella G.M.} and Bov{\'e}e, {Judith V.M.G.} and {Van Herpen}, {Carla M.L.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/hed.24556",
language = "English",
volume = "39",
pages = "140--146",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley Subscription Services, Inc., A Wiley Company Hoboken",
number = "1",

}

Boon, E, van der Graaf, WTA, Gelderblom, H, Tesselaar, MET, van Es, RJJ, Oosting, SF, de Bree, R, van Meerten, E, Hoeben, A, Smeele, LE, Willems, SM, Witjes, MJH, Buter, J, Baatenburg de Jong, RJ, Flucke, UE, Peer, PGM, Bovée, JVMG & Van Herpen, CML 2017, 'Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults' Head and Neck, vol. 39, no. 1, pp. 140-146. https://doi.org/10.1002/hed.24556

Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. / Boon, Eline; van der Graaf, Winette T.A.; Gelderblom, Hans; Tesselaar, Margot E.T.; van Es, Robert J.J.; Oosting, Sjoukje F.; de Bree, Remco; van Meerten, Esther; Hoeben, Ann; Smeele, Ludi E.; Willems, Stefan M.; Witjes, Max J.H.; Buter, Jan; Baatenburg de Jong, Robert J.; Flucke, Uta E.; Peer, Petronella G.M.; Bovée, Judith V.M.G.; Van Herpen, Carla M.L.

In: Head and Neck, Vol. 39, No. 1, 01.01.2017, p. 140-146.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

AU - Boon, Eline

AU - van der Graaf, Winette T.A.

AU - Gelderblom, Hans

AU - Tesselaar, Margot E.T.

AU - van Es, Robert J.J.

AU - Oosting, Sjoukje F.

AU - de Bree, Remco

AU - van Meerten, Esther

AU - Hoeben, Ann

AU - Smeele, Ludi E.

AU - Willems, Stefan M.

AU - Witjes, Max J.H.

AU - Buter, Jan

AU - Baatenburg de Jong, Robert J.

AU - Flucke, Uta E.

AU - Peer, Petronella G.M.

AU - Bovée, Judith V.M.G.

AU - Van Herpen, Carla M.L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. Results: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively). Conclusion: In patients younger than 75 years of age with surgically resected high- and intermediate-grade osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo-)adjuvant chemotherapy in patients amenable to chemotherapy.

AB - Background: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. Results: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively). Conclusion: In patients younger than 75 years of age with surgically resected high- and intermediate-grade osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo-)adjuvant chemotherapy in patients amenable to chemotherapy.

KW - (neo-)adjuvant

KW - chemotherapy

KW - head and neck neoplasms

KW - mandible

KW - maxilla

KW - osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84992455491&partnerID=8YFLogxK

U2 - 10.1002/hed.24556

DO - 10.1002/hed.24556

M3 - Article

VL - 39

SP - 140

EP - 146

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 1

ER -

Boon E, van der Graaf WTA, Gelderblom H, Tesselaar MET, van Es RJJ, Oosting SF et al. Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head and Neck. 2017 Jan 1;39(1):140-146. https://doi.org/10.1002/hed.24556